BioAnchor Announces One-Of-A-Kind Service for Mutation-Informed Biospecimens to Support Precision Diagnostics and Therapeutics
Exclusive molecular biorepository offering highlights BIOANCHOR’s novel platform to provide specific samples with rich data and mutation of interest
Los Angeles, Cali.--(BUSINESS WIRE)--BIOANCHOR, an innovative data-driven company transforming biorepository through the rapid delivery of mutation-informed biospecimens,announced today that the company has started its biobank services to the academic, clinical, diagnostic and pharmaceutical communities. The keystone of this unpredecented service is to provide mutation-harboring specimens in a highly customized way. The service, a first in US, leverages on large gene panel next-generation sequencing (NGS) technology and global networks to overcome current biorepository limitations associated with lack of molecular data, sourcing difficulty, high cost and long turnaround time.
BIOANCHOR’s digitalized sourcing and matching system serves as the foundation of the company’s one-of-its-kind biorepository offering. The sample search involves a seamless database mining process, resulting in improved outcome of high quality hits with comprehensive NGS mutation results. Successful cases include FFPE harboring EGFR exon 20 insertions or T790M; tissue samples positive for MET exon 14 skipping; or plasma samples with BRCA1/2 or ATM mutations.
“No two specimens are alike. Data-rich biospecimen offering is a cornerstone of our innovative approach to harness molecular diagnostics,” said BIOANCHOR Chief Operating Officer Peter Hong. “This exclusive and unique capability allows us to better serve our clients and partners through comprehensive genomic profiling of each sample we provide, leading to a transformative revolution in biorepository industry.”
“This is a breakthrough move in the world of biorepository,” continued Hong. “As therapies and companion diagnostics targeting tumors with specific gene mutations and gene fusions expand, specific genetic alteration-associated biospecimens has become essential for both Dx and Rx industry to further innovate their molecular tests and precision drugs.”
The exclusive offering will help BIOANCHOR continue to explore its benefits to consolidate the full potential of mutation-informed biospecimens, with advantages that will break biobank barrier:
· Comprehensive characterization of genetic alterations associated with every sample
· Expedite clinical test validation at CLIA/CAP and FDA/CE-IVD levels
· Facilitate Discovery of novel biomarkers and therapeutics for Dx and Rx purposes
· Enable clinical validation of innovative technology in a time- and cost-efficient manner
· Full integration of phenotype and genotype results
· Benefit more cancer patients with precision medicine
Broad applications of the BIOANCHOR’s fit-for-purpose biospecimens range from early cancer detection, treatment decision, drug resistance, minimal residual disease to immuno-oncology and gene and cell therapy.